CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$31.49
0.01 (0.03%)
â˛
5d:
+0.0%
30d:
+0.38%
90d:
+24.27%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CPRX is fairly priced but lacks strong directional signals. At 2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CPRX is fairly priced but lacks strong directional signals. At 2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$53.03
Based on 13.1% avg growth
INTRINSIC VALUE TODAY
$32.92
4.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $31.49, which is considered fair based on recent price action. The stock's valuation (Forward PE: 9.9) is in line with its historical norms (9.1). At these levels, the market is pricing in 2.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
51/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
63.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($31.67)
- NEUTRAL: Market pricing in 2.9% annual earnings growth - fairly valued
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$31.43
Resistance Level
$31.51
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.90
Wall Street Target
$31.67
(+0.6%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
11.1%
Profit Margin
37.1%
Valuation Premium vs History
+2.9% premium
PE vs Historical
9.9 vs 9.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$32.40
(+3%)
2-Year Target
$33.34
(+6%)
3-Year Target
$34.31
(+9%)
3-Yr Target (if PE normalizes)
(PE: 10â9)
PE COMPRESSION
$31.54
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.1%)
$69.74
(+122%)
Base:
(SPY PE: 9.9, Growth: 22.1%)
$31.70
(+1%)
Bear:
(PE: 8.4, Growth: 22.1%)
$26.94
(-14%)
Share & Embed Analysis
Last updated: August 18, 2026 12:49 AM ET
Data refreshes hourly during market hours. Next update: 1:49 AM
Data refreshes hourly during market hours. Next update: 1:49 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$372 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 29 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 50 HOLD |
